Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potential for Maternally Administered Vaccine for Infant Group B Streptococcus

19 Jul 2023

Abstract excerpt

BACKGROUND: Natural history studies have correlated serotype-specific anti-capsular polysaccharide (CPS) IgG in newborns with a reduced risk of group B streptococcal disease. A hexavalent CPS-cross-reactive material 197 glycoconjugate vaccine (GBS6) is being developed as a maternal vaccine to prevent invasive group B streptococcus in young infants. METHODS: In an ongoing phase 2, placebo-controlled trial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neonatal and Maternal Infections
Share to Preterm Birth and Chorioamnionitis
Share to Streptococcal Infections and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37467497
DOI: 10.1056/nejmoa2116045

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potential for Maternally Administered Vaccine for Infant Group B StreptococcusPMID 37467497Read ↗

Progress toward a group B streptococcal vaccineSemantic proximity Read ↗

Association between anti-capsular IgG levels at birth and risk of invasive group B streptococcus disease in Finnish newborns: a retrospective case–control studySemantic proximity Read ↗

Serological thresholds of risk reduction for infant group B streptococcus diseaseSemantic proximity Read ↗

Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against Group B Streptococcus in a randomised placebo-controlled double-blind phase 1 trial in healthy adult womenSemantic proximity Read ↗

Human systemic and mucosal immune responses support further exploration of a <i>Klebsiella pneumoniae</i> protein-based vaccineSemantic proximity Read ↗

Perinatal Infections Due to Group B StreptococciSemantic proximity Read ↗

Maternal immunisation against Group B Streptococcus: A global analysis of health impact and cost-effectivenessSemantic proximity Read ↗

Clinical and regulatory development strategies for GBS vaccines intended for maternal immunisation in low- and middle-income countriesSemantic proximity Read ↗

Novel Approaches to the Study of Neonatal Infections.Semantic proximity Read ↗

Safety and implementation of a phase 1 randomized GLA-SE-adjuvanted CH505TF gp120 HIV vaccine trial in newbornsSemantic proximity Read ↗

Recommendations for the Prevention of Perinatal Group B Streptococcal (GBS) DiseaseSemantic proximity Read ↗

Safety and immunogenicity of the group B streptococcus vaccine AlpN in a placebo-controlled double-blind phase 1 trialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.